Arrowhead Pharmaceuticals, Inc (ARWR) Sec Form 8K
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Sec Form 8K
18 articles, transcripts, and reports
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Sec Form 8K
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Q1 2026 Earnings Call dated Feb. 05, 2026 Corporate Participants: Vincent Anzalone — Head of...
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) FY 2026 Corporate Conference
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) FY 2026 Corporate Conference
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Q1 2026 Earnings Conference
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Sec Form 10Q
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Sec Form 8K
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Q2 2022 Earnings Call dated May. 10, 2022 Corporate Participants: Vincent Anzalone, CFA — Vice President, Head of Investor Relations…
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Q2 2025 Earnings Call dated May. 12, 2025 Corporate Participants: Vince Anzalone — Vice President, Investor Relations Christopher Anzalone —…
Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Q3 2025 Earnings Call dated Aug. 07, 2025 Corporate Participants: Vincent Anzalone — Vice President and Head of Investor Relations…